Veloxis Pharmaceuticals AS

Veloxis Pharmaceuticals A/S is a specialty pharmaceutical company founded in 2002 and headquartered in Hørsholm, Denmark, with a major U.S. office in Cary, North Carolina. Formerly known as LifeCycle Pharma A/S, the company operates as a wholly-owned subsidiary of the Japanese multinational corporation Asahi Kasei, following a $1.3 billion acquisition completed in March 2020. Veloxis employs around 120 people.

The company focuses on developing and commercializing products for transplant patients. Its primary product is ENVARSUS XR®, a once-daily, extended-release tablet formulation of the immunosuppressant drug tacrolimus, used for the prevention of organ rejection in kidney transplant patients. This product utilizes Veloxis's proprietary MeltDose® drug delivery technology, which is designed to improve the absorption and bioavailability of certain oral drugs. The company's pipeline includes other potential therapies for transplant recipients.

As an operating pharmaceutical company, Veloxis enforces its patent rights. The company's litigation profile shows it acting as a plaintiff to protect its commercial products, with one tracked case as a plaintiff and none as a defendant. This suit, Veloxis Pharmaceuticals AS v. Zydus Cadila et al., was filed in the Delaware District Court in April 2026. This type of litigation is common for brand-name drug manufacturers suing generic drug makers over patent challenges before the generic versions can enter the market.